Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer

References

• Rijavec E, Genova C, Alama A, et al. Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. Future Oncol. 2014;10(1):79–90.
   PubMed Web of Science ®Google Scholar
• Schvartsman G, Ferrarotto R, Massarelli E. Check-point inhibitors in lung cancer: latest developments and clinical potential. Ther Adv Med Oncol. 2016;8(6):460–473.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune check-points in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25–39.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. J Clin Oncol. 2016;39(1):98–106.
   PubMed Web of Science ®Google Scholar
• Helissey C, Champiat S, Soria JC. Immune check-point inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015;27(2):108–117.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Tanaka R, Asami Y, et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J Dermatol. 2016 Aug 11. [Epub ahead of print] DOI:10.1111/1346-8138.13520
   Web of Science ®Google Scholar
• Lo JA, Fisher DE, Flaherty KT. Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol. 2015 Dec;1(9):1340–1341.
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune check-point blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148.
   PubMed Web of Science ®Google Scholar
• Hasan Ali O, Diem S, Markert E, et al. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology. 2016;5(11):e1231292.
   PubMed Web of Science ®Google Scholar
• Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675–1682.
   PubMed Web of Science ®Google Scholar
• Davies M. New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res. 2014;6:63–75.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune check-point inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–265.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2980–2987.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
   PubMed Web of Science ®Google Scholar
• Besse B, Johnson M, Janne PA, et al. 16LBA phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Eur J Cancer. 2015;51(3):S717–8.
   Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–1846.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016 Dec 12; pii: S0140-6736(16)32517-X. [Epub ahead of print]. DOI:10.1016/S0140-6736(16)32517-X
   Web of Science ®Google Scholar
• Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41.
   PubMed Web of Science ®Google Scholar
• Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17(3):299–308.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2969–2979.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Quan Man Chow L, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J Clin Oncol. 2014;32(suppl; abstr 8022):5s.
   PubMedGoogle Scholar
• Gadgeel SM, Stevenson J, Langer CJ, et al. Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. J Clin Oncol. 2016;34(suppl; abstr 9016).
   Google Scholar
• Kroeze SG, Fritz C, Hoyer M, et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. Cancer Treat Rev. 2016;53:25–37.
   PubMed Web of Science ®Google Scholar
• Sundar R, Cho B-C, Brahmer JR, et al. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):85–96.
   PubMed Web of Science ®Google Scholar
• Opdivo prescribing information (Food and Drug Administration). [cited 2017 Jul 01]. Available from: http://www.access data.fda.gov/drugsatfda_docs/label/2015/125554s005lbl.pdf
   Google Scholar
• Keytruda prescribing information (Food and Drug Administration). [cited 2017 Jul 01]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s012lbl.pdf
   Google Scholar
• Bristol-Myers Squibb – Opdivo (Nivolumab) immune-mediated adverse reactions management guide. [cited 2017 Jul 01]. Availabel from: http://www.opdivoyervoyhcp.com/servlet/servlet.FileDownload?file=00Pi000000SRPWfEAP
   Google Scholar
• Merck Oncology - A guide to monitoring patients during treatment with keytruda. [cited 2017 Jul 01]. Available from: https://www.keytruda.com/static/pdf/Guide-to-Monitoring-Patients-During-Treatment-With-KEYTRUDA.pdf
   Google Scholar
• Horvat TZ, Adel NG, Dang T-O, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol. 2015;33(28):3193–3198.
   PubMed Web of Science ®Google Scholar
• Harmankaya K, Erasim C, Koelblinger C, et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol. 2011;28(4):1140–1144.
   PubMed Web of Science ®Google Scholar
• Villadolid J, Amin A. Immune check-point inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4(5):560–575.
   PubMed Web of Science ®Google Scholar
• Remicade prescribing information (Food and Drug Administration). [cited 2017 Aug 01]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf
   Google Scholar
• Del Castillo Garcia M, Redelman-Sidi G. Opportunistic infections in patients receiving immunotherapy with CTLA-4, PD-1 and PD-L1 blockers for treatment of metastatic melanoma. Open Forum Infect Dis. 2015;2(suppl 1). DOI:10.1093/ofid/ofv133.926
   Google Scholar
• Kyi C, Hellmann MD, Wolchok JD, et al. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer. 2014;2:19.
   PubMedGoogle Scholar
• Arriola E, Wheater M, Krishnan R, et al. Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. Oncoimmunology. 2015;4(10):e1040218.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Helbling D, Schmidt J, et al. Treatment-associated fatigue in cancer patients treated with immune check-point inhibitors; a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2016;28(10):e127–38.
   PubMed Web of Science ®Google Scholar
• Dev R, Wong A, Hui D, et al. The evolving approach to management of cancer cachexia. Oncology (Williston Park). 2017;31(1).
   PubMed Web of Science ®Google Scholar
• Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune check-point antibodies. Ann Oncol. 2016;27(7):1362.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71(1):161–169.
   PubMed Web of Science ®Google Scholar
• Pintova S, Sidhu H, Friedlander PA, et al. Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res. 2013;23(6):498–501.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–1030.
   PubMed Web of Science ®Google Scholar
• Weber JS, Yang JC, Atkins MB, et al. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092–2099.
   PubMed Web of Science ®Google Scholar
• American Dietetic Association - Crohn’s Disease and Ulcerative Colitis Nutrition Therapy. [cited 2017 Oct 01]. Available from: http://www.uccs.edu/Documents/peakfood/hlthTopics/Crohns%20Disease%20Nutrition.pdf
   Google Scholar
• Edsbäcker S, Bengtsson B, Larsson P, et al. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther. 2003;17(4):525–536.
   PubMed Web of Science ®Google Scholar
• Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15(17):5591–5598.
   PubMed Web of Science ®Google Scholar
• Pagès C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23(3):227–230.
   PubMed Web of Science ®Google Scholar
• Gonzalez RS, Salaria SN, Bohannon CD, et al. PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’. Histopathology. 2016 Nov 7. [Epub ahead of print]. DOI:10.1111/his.13118
   PubMed Web of Science ®Google Scholar
• Spain L, Diem S, Larkin J. Management of toxicities of immune check-point inhibitors. Cancer Treat Rev. 2016;44:51–60.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57(8):2233–2240.
   PubMed Web of Science ®Google Scholar
• Gelsomino F, Vitale G, D’Errico A, et al. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol. 2016 Dec 19;pii: mdw649. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Parekh R, Kaur N. Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature. Case Rep Gastrointest Med. 2014;2014:956463.
   PubMedGoogle Scholar
• Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune check-point inhibitors: a meta-analysis. Ther Adv Respir Dis. 2016;10(3):183–193.
   PubMed Web of Science ®Google Scholar
• Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(12):1607–1616.
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051–6060.
   PubMed Web of Science ®Google Scholar
• Gounant V, Brosseau S, Naltet C, et al. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. Lung Cancer. 2016;99:162–165.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Kimura H, Takato H, et al. Severe pneumonitis after nivolumab treatment in a patient with melanoma. Allergol Int. 2016;65(4):487–489.
   PubMed Web of Science ®Google Scholar
• Nishino M, Chambers ES, Chong CR, et al. Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res. 2016;4(4):289–293.
   PubMed Web of Science ®Google Scholar
• Martin-Liberal J, Furness AJ, Joshi K, et al. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother. 2015;64(6):765–767.
   PubMed Web of Science ®Google Scholar
• Rossi G, Albertelli M, Nazzari E, et al. Endocrinological side-effects of nivolumab in advanced non-small cell lung cancer. 17th world conference on lung cancer. 4-7 december 2016, Vienna, Austria. J Torac Oncol. 2017;12(S1):S681 (P3.02C-039).
   PubMedGoogle Scholar
• Abdel-Rahman O, ElHalawani H, Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncol. 2016;12(3):413–425.
   PubMed Web of Science ®Google Scholar
• Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune check-point inhibitors. Curr Opin Oncol. 2016;28(4):278–287.
   PubMed Web of Science ®Google Scholar
• Rossi E, Sgambato A, De Chiara G, et al. Endocrinopathies induced by immune-check-point inhibitors in advanced non-small cell lung cancer. Expert Rev Clin Pharmacol. 2016;9(3):419–428.
   PubMed Web of Science ®Google Scholar
• Okano Y, Satoh T, Horiguchi K, et al. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J. 2016;63(10):905–912.
   PubMed Web of Science ®Google Scholar
• Tanaka R, Fujisawa Y, Maruyama H, et al. Nivolumab-induced thyroid dysfunction. Jpn J Clin Oncol. 2016;46(6):575–579.
   PubMed Web of Science ®Google Scholar
• Orlov S, Salari F, Kashat L, et al. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. J Clin Endocrinol Metab. 2015;100(5):1738–1741.
   PubMed Web of Science ®Google Scholar
• Verma I, Modi A, Tripathi H, et al. Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung. BMJ Case Rep. 2016;2016:pii: bcr2015213692.
   Google Scholar
• Corsello SM, Barnabei A, Marchetti P, et al. Endocrine side effects induced by immune check-point inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361–1375.
   PubMed Web of Science ®Google Scholar
• Trainer H, Hulse P, Higham CE, et al. Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinol Diabetes Metab Case Rep. 2016;2016:pii: 16-0108. Epub 2016 Nov 1
   PubMedGoogle Scholar
• Cappelli LC, Gutierrez AK, Bingham CO 3rd, et al. Rheumatic and musculoskeletal immune-related adverse events due to immune check-point inhibitors: A systematic review of the literature. Arthritis Care Res (Hoboken). 2016 Dec 20. [Epub ahead of print]. DOI:10.1002/acr.23177
   PubMed Web of Science ®Google Scholar
• Law-Ping-Man S, Martin A, Briens E, et al. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology (Oxford). 2016;55(11):2087–2089.
   PubMed Web of Science ®Google Scholar
• Syrigos K, Tsagouli S, Grapsa D. Nivolumab-induced recurrence of rheumatoid arthritis in a patient with advanced non-small cell lung cancer: a case report. Ann Intern Med. 2016;165(12):894–895.
   PubMed Web of Science ®Google Scholar
• Salmon JH, Lambrecht I, Brochot P, et al. A case of arthritis under pembrolizumab. Joint Bone Spine. 2016 Apr 22:pii: S1297-319X(16)30017-3. [Epub ahead of print]. DOI:10.1016/j.jbspin.2016.03.003
   Web of Science ®Google Scholar
• Chan MM, Kefford RF, Carlino M, et al. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother. 2015;38(1):37–39.
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76(1):43–50.
   PubMed Web of Science ®Google Scholar
• Roberts P, Fishman GA, Joshi K, et al. Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab. JAMA Ophthalmol. 2016;134(10):1184–1188.
   PubMed Web of Science ®Google Scholar
• Abu Samra K, Valdes-Navarro M, Lee S, et al. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol. 2016;26(3):e46–8.
   PubMed Web of Science ®Google Scholar
• Aaberg MT, Aaberg TM Jr. Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep. 2016 Aug 2. Epub ahead of print
   PubMedGoogle Scholar
• Antoun J, Titah C, Cochereau I. Ocular and orbital side-effects of check-point inhibitors: a review article. Curr Opin Oncol. 2016;28(4):288–294.
   PubMed Web of Science ®Google Scholar
• Le Fournis S, Gohier P, Urban T, et al. Corneal graft rejection in a patient treated with nivolumab for primary lung cancer. Lung Cancer. 2016;102:28–29.
   PubMed Web of Science ®Google Scholar
• Hottinger AF. Neurologic complications of immune check-point inhibitors. Curr Opin Neurol. 2016;29(6):806–812.
   PubMed Web of Science ®Google Scholar
• Wilson MA, Guld K, Galetta S, et al. Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer. 2016;4:66.
   PubMed Web of Science ®Google Scholar
• Abe J, Sato T, Tanaka R, et al. Nivolumab-induced severe akathisia in an advanced lung cancer patient. Am J Case Rep. 2016;17:880–882.
   PubMed Web of Science ®Google Scholar
• Jung K, Zeng X, Bilusic M. Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrol. 2016;17(1):188.
   PubMed Web of Science ®Google Scholar
• Belliere J, Meyer N, Mazieres J, et al. Acute interstitial nephritis related to immune check-point inhibitors. Br J Cancer. 2016;115(12):1457–1461.
   PubMed Web of Science ®Google Scholar
• Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune check-point inhibitors: a narrative review. Am J Nephrol. 2017 Jan 12;45(2): 160–169. [Epub ahead of print] DOI:10.1159/000455014
   PubMed Web of Science ®Google Scholar
• Nair R, Gheith S, Nair SG. Immunotherapy-associated hemolytic anemia with pure red-cell aplasia. N Engl J Med. 2016;374(11):1096–1097.
   PubMed Web of Science ®Google Scholar
• Kong BY, Micklethwaite KP, Swaminathan S, et al. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res. 2016;26(2):202–204.
   PubMed Web of Science ®Google Scholar
• Simeone E, Grimaldi AM, Esposito A, et al. Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep. 2014;8:240.
   PubMedGoogle Scholar
• Du Rusquec P, Saint-Jean M, Brocard A, et al. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother. 2014;37(6):348–350.
   PubMed Web of Science ®Google Scholar
• Ikeuchi K, Okuma Y, Tabata T. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. Lung Cancer. 2016;99:148–150.
   PubMed Web of Science ®Google Scholar
• Alabed YZ, Aghayev A, Sakellis C, et al. Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET/CT. Clin Nucl Med. 2015;40(11):e528–9.
   PubMed Web of Science ®Google Scholar
• Kushnir I, Wolf I. Nivolumab-induced pericardial tamponade: a case report and discussion. Cardiology. 2017;136(1):49–51.
   PubMed Web of Science ®Google Scholar
• Semper H, Muehlberg F, Schulz-Menger J, et al. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer. 2016;99:117–119.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755.
   PubMed Web of Science ®Google Scholar
• Rijavec E, Genova C, Sarocchi M, et al. Cardiac troponin-I elevation in patients with non-small cell lung cancer during PD1/PDL1 inhibition with nivolumab. 17th world conference on lung cancer. 4-7 december 2016, Vienna, Austria. J Torac Oncol. 2017;12(S1):S695(P3.02C-077).
   Google Scholar
• Ben Amar J, Zaibi H, Bouzid K, et al. Role of procalcitonin and c-reactive protein levels: a diagnostic tool in lower respiratory tract infections. Tunis Med. 2016;94(3):176–180.
   PubMedGoogle Scholar
• [cited 2017 Jan 24]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02039674?term=pembrolizumab+chemotherapy&rank=23
   Google Scholar
• Lee CS, Thomas CM, Ng KE. An Overview of the changing landscape of treatment for advanced melanoma. Pharmacotherapy. 2017 Jan;4. [Epub ahead of print]. DOI:10.1002/phar.1895
   Web of Science ®Google Scholar
• Kanz BA, Mh P 1st, Johnpulle R, et al. Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer. 2016;4:60.
   PubMed Web of Science ®Google Scholar
• Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2016 Sep 29; pii: mdw443. [Epub ahead of print] DOI:10.1093/annonc/mdw443. .
   PubMed Web of Science ®Google Scholar
• Davar D, Wilson M, Pruckner C, et al. PD-1 Blockade in advanced melanoma in patients with hepatitis C and/or HIV. Case Rep Oncol Med. 2015;2015:737389.
   PubMed Web of Science ®Google Scholar
• Elias R, Morales J, Rehman Y, et al. Immune checkpoint inhibitors in older adults. Curr Oncol Rep. 2016;18(8):47.
   PubMed Web of Science ®Google Scholar